Longitudinal prescription data analysis observes treatment patterns in relapsing-remitting multiple sclerosis at year five, highlighting real-world cladribine therapy trajectories.
To describe treatment patterns and characteristics of patients with highly active relapsing-remitting multiple sclerosis (RRMS) in Germany who reached year (Y)5 after initiating treatment with cladribine tablets (CladT).
No takes yet. Share an insight, caveat, or question.
Maßen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: